Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF)

• Verfasst von: Rosell, Rafael [VerfasserIn]
• Verfasst von: Thomas, Michael [VerfasserIn]
• Titel: Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF)
• Titelzusatz: an international, multicentre, single-arm, phase 2 trial
• Verf.angabe: Prof Rafael Rosell, MD, Prof Urania Dafni, ScD, Enriqueta Felip, MD, Alessandra Curioni-Fontecedro, MD, Oliver Gautschi, MD, Solange Peters, MD, Bartomeu Massutí, MD, Ramon Palmero, MD, Santiago Ponce Aix, MD, Enric Carcereny, MD, Martin Früh, MD, Miklos Pless, MD, Sanjay Popat, FRCP, Athanasios Kotsakis, MD, Sinead Cuffe, MD, Paolo Bidoli, MD, Adolfo Favaretto, MD, Patrizia Froesch, MD, Noemí Reguart, MD, Javier Puente, MD, Linda Coate, MD, Prof Fabrice Barlesi, MD, Daniel Rauch, MD, Prof Michael Thomas, MD, Carlos Camps, MD, Jose Gómez-Codina, MD, Margarita Majem, MD, Rut Porta, MD, Riyaz Shah, FRCP, Emer Hanrahan, MRCPI, Roswitha Kammler, BA, Barbara Ruepp, PharmD, Manuela Rabaglio, MD, Marie Kassapian, MSc, Niki Karachaliou, MD, Rachel Tam, BSc, David S Shames, PhD, Miguel A Molina-Vila, PhD, Dr Rolf A Stahel for the BELIEF collaborative group
• Umfang: 10 S.
• Fussnoten: Gesehen am 18.04.2018
• Titel Quelle: Enthalten in: The lancet <London> / Respiratory medicine
• Jahr Quelle: 2017
• Band/Heft Quelle: 5(2017), 5, S. 435-444
• ISSN Quelle: 2213-2619
• DOI: doi:10.1016/S2213-2600(17)30129-7
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1572115203

Abstract

Summary: The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the T790M resistance mutation with another EGFR mutation in treatment-naive patients has been associated with a shorter progression-free survival to EGFR inhibition than in the absence of the T790M mutation. To test this hypothesis clinically, we developed a proof-of-concept study, in which patients with EGFR-mutant NSCLC were treated with the combination of erlotinib and bevacizumab, stratified by the presence of the pretreatment T790M mutation.